Predict your next investment

DEMECAN company logo
AGRICULTURE | Crop Production
demecan.de

See what CB Insights has to offer

Founded Year

2017

Stage

Debt | Alive

Total Raised

$8.88M

Last Raised

$1.2M | 7 mos ago

About DEMECAN

DEMECAN produces medical cannabis. The startup covers the entire value chain for medical cannabis from cultivation, processing and storage to distribution for pharmacies.

DEMECAN Headquarter Location

Reichenberger Strasse 120

Berlin, 10999,

Germany

Latest DEMECAN News

Demecan On-Track To Hit Early 2022 Harvest After Fund-Raising Boost

Aug 10, 2021

Demecan On-Track To Hit Early 2022 Harvest After Fund-Raising Boost August 9, 2021 GERMANY’s sole domestic cannabis producer is expected to harvest its first crop in early 2022 after securing additional investment to complete its production facility. Demecan , which was founded in 2017, is one of three companies permitted to cultivate cannabis in Germany by the Federal Institute for Drugs and Medical Devices. Some 4,000 cannabis plants will be sowed in October at its new facility near Dresden, with the first products to be delivered early next year. This follows a successful fund-raising round – in the ‘upper single-digit million range’ – from private and institutional investors, including the Futury Fund as well as existing shareholders, including the btov Private Investor Network. Harvest As Quickly As Possible Dr Constantin von der Groeben, Co-Founder and CEO of Demecan, told BusinessCann: “The investment is to used for further growth as well as the expansion of the production facility into Europe’s most modern facility for the cultivation and processing of medicinal cannabis. “Under current conditions, Demecan plans to complete the manufacturing facility in the third quarter of 2021 and harvest as quickly as possible.” Demecan is converting a former slaughterhouse on an 100,000 sq ms plot of land into an indoor production facility with office space and a laboratory. Demecan’s cultivation facilities in Ebersbach, South East Germany The halls are currently under construction with the installation of air filter systems, water tanks and around 150 video cameras. When sowed 1,000 plants will grow in each of the four halls. The labour-intensive operation is expected to initially employ around 80 people. Initially, Demecan aims to harvest up to one tonne of cannabis and its three founders believe that as the German market grows it will move towards its capacity of around 10 tonnes per year. Last month Canadian company Tilray became the first of the three producers to deliver homegrown flower in to the market through its subsidiary Aphria. The third supplier is fellow Canadian company Aurora. Seven Million Euros The Federal Institute’s total permitted cultivation amount is 10.4 tonnes of medicinal cannabis over four years. In April this year Demecan closed its latest multi-million Euro financing round, with Dr Adrian Fischer, physician, co-founder, and CEO saying: “It is Demecan’s mission to guarantee the nationwide supply of high-quality medical cannabis for the benefit of patients in Germany. “Therefore, we not only focus on the cultivation of medical cannabis but are also active in the field of R&D to develop new and innovative dosage forms.” Demecan says it intends to establish a subsidiary in the state of Hessen with the aim of establishing a dedicated medical cannabis research cluster. In 2019, the Berlin startup has received seven million euros in a Series A financing round . Half of the investment came from the private investor network of the European venture capitalist btov Partners. The other half came from a German entrepreneurial family. Peter McCusker is the Founder and Editor of BusinessCann and an experienced news and business editor, who believes it’s time to fully embrace the multiple, proven, medical benefits of the cannabis plant. BusinessCann covers the ins and outs of the growing European Regulated Medical Marijuana marketplace. Peter can be reached at [email protected] . BusinessCann  is an online news publication, which supports the growth of Europe’s Hemp, CBD and Medicinal Cannabis industries by providing factual and feature articles, comment and profiles on the people and businesses forging its growth and development. This Post Has 0 Comments Leave a Reply

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing DEMECAN

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

DEMECAN is included in 1 Expert Collection, including Cannabis.

C

Cannabis

3,613 items

These companies participate in - or service businesses that participate in - the legal cannabis industry. Our definition of cannabis includes both marijuana and hemp (and all derivatives). The collection includes both "plant-touching" and "non-plant-touching" businesses.

DEMECAN Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

DEMECAN Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.